Navepegritide for achondroplasia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Oct 2023: Trial registered, NCT06079398
  2. 23 Jan 2024: Trial started, NCT06079398

The trials

NCT06079398: A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

State
Under way
Phase
Phase 2
People
72 planned
Started
23 Jan 2024
Primary completion
Dec 2027
Arms
Navepegritide
Results
None posted
  1. 12 Oct 2023: Trial registered
  2. 23 Jan 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Yuviwel.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.